408 related articles for article (PubMed ID: 11327251)
1. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
Gardinali M; Pozzi MR; Bernareggi M; Montani N; Allevi E; Catena L; Cugno M; Bottasso B; Stabilini R
J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251
[TBL] [Abstract][Full Text] [Related]
2. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
3. Effects of prostaglandin E1alpha cyclodextrin [corrected] treatment on endothelial dysfunction in patients with systemic sclerosis.
Giannattasio C; Pozzi M; Gardinali M; Montemerlo E; Citterio F; Maestroni S; Fantini E; Failla M; Robuschi M; Bianco S; Mancia G
J Hypertens; 2007 Apr; 25(4):793-7. PubMed ID: 17351371
[TBL] [Abstract][Full Text] [Related]
4. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.
Dziadzio M; Denton CP; Smith R; Howell K; Blann A; Bowers E; Black CM
Arthritis Rheum; 1999 Dec; 42(12):2646-55. PubMed ID: 10616013
[TBL] [Abstract][Full Text] [Related]
5. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
[TBL] [Abstract][Full Text] [Related]
6. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study.
Sambo P; Amico D; Giacomelli R; Matucci-Cerinic M; Salsano F; Valentini G; Gabrielli A
J Rheumatol; 2001 Oct; 28(10):2257-62. PubMed ID: 11669166
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon.
Blann AD; Illingworth K; Jayson MI
J Rheumatol; 1993 Aug; 20(8):1325-30. PubMed ID: 8230013
[TBL] [Abstract][Full Text] [Related]
8. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
[TBL] [Abstract][Full Text] [Related]
9. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels.
Polisson RP; Gilkeson GS; Pyun EH; Pisetsky DS; Smith EA; Simon LS
J Rheumatol; 1996 Apr; 23(4):654-8. PubMed ID: 8730122
[TBL] [Abstract][Full Text] [Related]
10. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
[TBL] [Abstract][Full Text] [Related]
11. Cold stimulus fingertip lacticemy test--an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis.
Fontenelle SM; Kayser C; Pucinelli ML; Andrade LE
Rheumatology (Oxford); 2008 Jan; 47(1):80-3. PubMed ID: 18077495
[TBL] [Abstract][Full Text] [Related]
12. Homocysteine concentration in primary and systemic sclerosis associated Raynaud's phenomenon.
Marasini B; Casari S; Bestetti A; Maioli C; Cugno M; Zeni S; Turri O; Guagnellini E; Biondi ML
J Rheumatol; 2000 Nov; 27(11):2621-3. PubMed ID: 11093443
[TBL] [Abstract][Full Text] [Related]
13. Seasonal variation of Raynaud's phenomenon secondary to systemic sclerosis.
Watson HR; Robb R; Belcher G; Belch JJ
J Rheumatol; 1999 Aug; 26(8):1734-7. PubMed ID: 10451070
[TBL] [Abstract][Full Text] [Related]
14. Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study.
Pamuk GE; Turgut B; Pamuk ON; Vural O; Demir M; Cakir N
Blood Coagul Fibrinolysis; 2007 Jun; 18(4):297-302. PubMed ID: 17473568
[TBL] [Abstract][Full Text] [Related]
15. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
Cordioli E; Virgilio S; Ghirardi R; Martinelli M
Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297
[TBL] [Abstract][Full Text] [Related]
16. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
Bartolone S; Trifiletti A; De Nuzzo G; Scamardi R; Larosa D; Sottilotta G; Raffa A; Barbera N
Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
[TBL] [Abstract][Full Text] [Related]
17. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
[TBL] [Abstract][Full Text] [Related]
18. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.
Rychlik-Golema W; Mastej K; Adamiec R
Int Angiol; 2006 Jun; 25(2):221-7. PubMed ID: 16763543
[TBL] [Abstract][Full Text] [Related]
19. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
[TBL] [Abstract][Full Text] [Related]
20. Vascular damage and lack of angiogenesis in systemic sclerosis skin.
Konttinen YT; Mackiewicz Z; Ruuttila P; Ceponis A; Sukura A; Povilenaite D; Hukkanen M; Virtanen I
Clin Rheumatol; 2003 Sep; 22(3):196-202. PubMed ID: 14505210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
